 | | PRD_000672 | | Name: | CBZ-ASP-GLU-VAL-azaASP-EP-CO-NH-CH2PH | | Formula: | C35 H44 N6 O14 | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_000673 | | Name: | CBZ-ASP-GLU-VAL-azaASP-EP-COO-CH2PH | | Formula: | C35 H43 N5 O15 | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_000674 | | Name: | CBZ-ASP-GLU-VAL-azaASP-EP-CO-N(CH2PH)2 | | Formula: | C42 H50 N6 O14 | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_002314 | | Name: | INNN(ABU) Cyclic peptide inhibitor | | Formula: | C22 H36 N8 O8 | | Definition date: | 2019-04-17 | | Last modified: | 2023-11-03 |
|
 | | PRD_000727 | | Name: | PYOVERDIN G173 Fe Complex | | Formula: | C49 H66 Fe N13 O21 | | Description: | IN IRON-DEFICIENT CONDITIONS, PSEUDOMONAS
AERUGINOSA SECRETES A MAJOR FLUORESCENT
SIDEROPHORE NAMED PYOVERDIN (PVD),
WHICH AFTER CHELATING IRON(III) IS TRANSPORTED
BACK INTO THE CELL VIA ITS OUTER MEMBRANE RECEPTOR
FPVA. FPVA IS A TONB-DEPENDENT TRANSPORT PROTEIN
AND HAS THE ABILITY TO BIND PVD IN ITS APO-
OR IRON-LOADED FORM. | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_002338 | | Name: | N-(3-phenylpropanoyl)-3-(1,3-thiazol-4-yl)-L-alanyl-N-[(1S,2S)-1-(1,3-benzothiazol-2-yl)-5-carbamimidamido-1-hydroxypentan-2-yl]-L-valinamide | | Formula: | C33 H42 N8 O4 S2 | | Definition date: | 2019-10-02 | | Last modified: | 2023-11-03 |
|
 | | PRD_000770 | | Name: | (5S, 8R, 11S)-14-[4-(BENZYLOXY)-4-OXOBUTANOYL]-8-(2-CARBOXYETHYL)-5-(CARBOXYMETHYL)-11-
(1-METHYLETHYL)-3,6,9,12-TETRAOXO-1-PHENYL-2-OXA-4,7,10,13,14-PENTAAZAHEXADECAN-16-OIC ACID | | Formula: | C35 H43 N5 O14 | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_002350 | | Name: | INHIBITOR ARC-1415 | | Formula: | C55 H106 N30 O8 | | Definition date: | 2021-08-04 | | Last modified: | 2023-11-03 |
|
 | | PRD_000781 | | Name: | Thr-Asp-F-amidine | | Formula: | C17 H29 F N6 O7 | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_002363 | | Formula: | C73 H120 N20 O13 | | Definition date: | 2020-08-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_000785 | | Name: | Largazole | | Formula: | C21 H29 N4 O4 S3 | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_002365 | | Name: | phazolicin | | Formula: | C74 H104 N29 O27 S3 | | Definition date: | 2020-08-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_002369 | | Name: | ecumicin | | Formula: | C83 H135 N14 O17 | | Definition date: | 2020-05-13 | | Last modified: | 2023-11-03 |
|
 | | PRD_002390 | | Name: | Papain-like protease peptide inhibitor VIR251 | | Formula: | C22 H33 N5 O7 | | Definition date: | 2020-05-20 | | Last modified: | 2023-11-03 |
|
 | | PRD_002391 | | Name: | covalently bound calpain inhibitor II | | Formula: | C19 H37 N3 O4 S | | Definition date: | 2020-06-17 | | Last modified: | 2023-11-03 |
|
 | | PRD_002392 | | Name: | UAW246 | | Formula: | C25 H36 N4 O6 | | Definition date: | 2020-06-17 | | Last modified: | 2023-11-03 |
|
 | | PRD_002394 | | Name: | UAW248 | | Formula: | C30 H45 N5 O7 | | Definition date: | 2020-06-17 | | Last modified: | 2023-11-03 |
|
 | | PRD_000814 | | Name: | N-{[(3R,4R,7S,10R,11R)-3-ethyl-11,15-dihydroxy-3-methyl-10-(methylamino)-6,9-dioxo-7-(propan-2-yl)-2-oxa-5,8-diazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-4-yl]carbonyl}glycine | | Formula: | C23 H34 N4 O8 | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_000823 | | Name: | N-propanoyl-D-alanyl-(4R)-4-[(7-bromoisoquinolin-1-yl)oxy]-N-{(1R,2R)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-L-prolinamide | | Formula: | C29 H34 Br N5 O7 S | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_000842 | | Name: | PTA-SFTI INHIBITOR | | Formula: | C66 H106 N20 O18 S2 | | Description: | Bowman-Birk Inhibitor | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_000845 | | Name: | N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-7-methoxy-2-{2-[(2-methylpropanoyl)amino]-1,3-thiazol-4-yl}quinolin-4-yl)oxy]-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-L-prolinamide | | Formula: | C40 H49 Br N6 O9 S | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_000846 | | Name: | TRYPSIN INHIBITOR 1 | | Formula: | C66 H106 N20 O18 S2 | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_000849 | | Name: | N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-{2-[(2-methylpropanoyl)amino]-1,3-thiazol-4-yl}quinolin-4-yl)oxy]-L-prolinamide | | Formula: | C40 H50 N6 O9 S | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_000857 | | Name: | SAH-p53-8 stapled-peptide | | Formula: | C96 H151 N26 O25 | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_002417 | | Name: | Ac-VRHA-conh-[4-(4-butyl)-phenoxy-1-phenyl-2-butyl] | | Formula: | C43 H66 N10 O7 | | Definition date: | 2023-10-25 | | Last modified: | 2023-10-25 |
|
